4D Molecular Therapeutics Inc
NASDAQ:FDMT
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Price:
25.64 USD
0.23%
Market Closed
Updated:
May 18, 2024
P/E
Price to Earnings
Price to Earnings
-7.6
Current
-6.8
Median
26.1
Industry
Lower
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-7.6
Market Cap
/
1.3B
Net Income
-173.1m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
4D Molecular Therapeutics Inc
NASDAQ:FDMT
|
1.3B USD | -7.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
293.9B USD | 61 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
167.5B USD | 44.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.7B USD | 31.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.2B USD | 28.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.3B AUD | 36.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.1B USD | 173.7 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
50.7B USD | -8.5 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.5B USD | 28.7 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.7T KRW | 74.1 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-8.4
2-Years Forward
P/E
-7.6
3-Years Forward
P/E
-5.6
You don't have any saved screeners yet
